BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus EV Jr, Ostad-Saffari E, Scalori A, Oh YS, Tole S, Chai A, Pulley J, Lacey S, Sandborn WJ; HICKORY Study Group. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Lancet Gastroenterol Hepatol 2021:S2468-1253(21)00298-3. [PMID: 34798039 DOI: 10.1016/S2468-1253(21)00298-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Sandborn WJ, Panés J, Danese S, Sharafali Z, Hassanali A, Jacob-moffatt R, Eden C, Daperno M, Valentine JF, Laharie D, Baía C, Atreya R, Panaccione R, Rydzewska G, Aguilar H, Vermeire S. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00303-x] [Reference Citation Analysis]
2 Vieujean S, D’amico F, Netter P, Danese S, Peyrin‐biroulet L. Landscape of new drugs and targets in inflammatory bowel disease. UEG Journal. [DOI: 10.1002/ueg2.12305] [Reference Citation Analysis]
3 Moein A, Lu T, Jönsson S, Ribbing J, Kassir N, Zhang W, Sperinde G, Zhang R, Tang M, Oh YS, Bruno R, Zhu R. Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis. CPT Pharmacom & Syst Pharma 2022;11:1244-1255. [DOI: 10.1002/psp4.12846] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kassir N, Zhu R, Moein A, Langenhorst J, Ribbing J, Zhang R, Tang MT, Oh YS, Zhang W. Exposure‐response relationships of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis. CPT Pharmacom & Syst Pharma 2022;11:1234-1243. [DOI: 10.1002/psp4.12840] [Reference Citation Analysis]
5 Song Y, Yuan M, Xu Y, Xu H. Tackling Inflammatory Bowel Diseases: Targeting Proinflammatory Cytokines and Lymphocyte Homing. Pharmaceuticals 2022;15:1080. [DOI: 10.3390/ph15091080] [Reference Citation Analysis]
6 Ganesh N, van der Vorst EPC, Spiesshöfer J, He S, Burgmaier M, Findeisen H, Lehrke M, Swirski FK, Marx N, Kahles F. Gut immune cells—A novel therapeutical target for cardiovascular disease? Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.943214] [Reference Citation Analysis]
7 Zundler S, Günther C, Kremer AE, Zaiss MM, Rothhammer V, Neurath MF. Gut immune cell trafficking: inter-organ communication and immune-mediated inflammation. Nat Rev Gastroenterol Hepatol 2022. [PMID: 35945456 DOI: 10.1038/s41575-022-00663-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Jiang P, Zheng C, Xiang Y, Malik S, Su D, Xu G, Zhang M. The involvement of TH17 cells in the pathogenesis of IBD. Cytokine Growth Factor Rev 2022:S1359-6101(22)00053-3. [PMID: 35871978 DOI: 10.1016/j.cytogfr.2022.07.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Schweda A, Becker E, Wiendl M, Atreya R, Atreya I, Müller TM, Neurath MF, Zundler S. Etrolizumab-s Does Not Induce Residual Trafficking of Regulatory T Cells. Inflamm Bowel Dis 2022:izac137. [PMID: 35815779 DOI: 10.1093/ibd/izac137] [Reference Citation Analysis]
10 Sekhri S, Yarur AJ. Integrating new and emerging therapies into inflammatory bowel disease clinical practice. Curr Opin Gastroenterol 2022;38:328-36. [PMID: 35762692 DOI: 10.1097/MOG.0000000000000851] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Toskas A, Akbar A. IBD therapeutics: what is in the pipeline? Frontline Gastroenterol 2022;13:e35-43. [DOI: 10.1136/flgastro-2022-102130] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Zhang L, Mao R, Lau CT, Chung WC, Chan JCP, Liang F, Zhao C, Zhang X, Bian Z. Identification of useful genes from multiple microarrays for ulcerative colitis diagnosis based on machine learning methods. Sci Rep 2022;12:9962. [PMID: 35705632 DOI: 10.1038/s41598-022-14048-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Hernandez Santana YE, Irwin N, Walsh PT. IL-36: a therapeutic target for ulcerative colitis? Expert Opin Ther Targets 2022;:1-6. [PMID: 35634891 DOI: 10.1080/14728222.2022.2084381] [Reference Citation Analysis]
14 Burr NE, Gracie DJ, Black CJ, Ford AC. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. Gut 2021:gutjnl-2021-326390. [PMID: 34937767 DOI: 10.1136/gutjnl-2021-326390] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
15 Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 2021:S2468-1253(21)00377-0. [PMID: 34856198 DOI: 10.1016/S2468-1253(21)00377-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 16.0] [Reference Citation Analysis]
16 Agrawal M, Verstockt B. Etrolizumab for ulcerative colitis: beyond what meets the eye. Lancet Gastroenterol Hepatol 2022;7:2-4. [PMID: 34798035 DOI: 10.1016/S2468-1253(21)00369-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]